Oxidative modification of LDL: its pathological role in atherosclerosis
- PMID: 18987785
- DOI: 10.1007/s12016-008-8095-9
Oxidative modification of LDL: its pathological role in atherosclerosis
Abstract
Oxidized low-density lipoprotein (OxLDL) is a well-known risk marker for cardiovascular diseases. OxLDL has shown a variety of proatherogenic properties in experiments performed in vitro. In addition, immunological studies using monoclonal antibodies have revealed the occurrence of OxLDL in vivo in atherosclerotic lesions and patients' plasma specimens. Resent clinical studies have indicated the prospective significance of plasma OxLDL measurements; however, the behavior and metabolism of OxLDL in vivo is poorly understood. The mechanism by which LDL is oxidized is not clear, and the modified structures of OxLDL are not yet fully understood, partly because OxLDL is a mixture of heterogeneously modified particles. Here, I discuss the recent studies on oxidative modifications in OxLDL and its clinical and pathological features.
Similar articles
-
[Atherosclerosis and sensitive determination of oxidized LDL using monoclonal antibody].Yakugaku Zasshi. 2002 Oct;122(10):745-53. doi: 10.1248/yakushi.122.745. Yakugaku Zasshi. 2002. PMID: 12400156 Review. Japanese.
-
Oxidized low-density lipoproteins: what is understood and what remains to be clarified.Biol Pharm Bull. 2003 Jan;26(1):1-9. doi: 10.1248/bpb.26.1. Biol Pharm Bull. 2003. PMID: 12520163 Review.
-
Oxidized low density lipoprotein: the occurrence and metabolism in circulation and in foam cells.J Atheroscler Thromb. 2000;7(3):123-31. doi: 10.5551/jat1994.7.123. J Atheroscler Thromb. 2000. PMID: 11480452 Review.
-
Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins.Med Sci Monit. 2004 Jul;10(7):BR207-14. Epub 2004 Jun 29. Med Sci Monit. 2004. PMID: 15232494
-
Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit.Am J Pathol. 1989 Nov;135(5):815-25. Am J Pathol. 1989. PMID: 2683796 Free PMC article.
Cited by
-
TET2 Protects against oxLDL-Induced HUVEC Dysfunction by Upregulating the CSE/H2S System.Front Pharmacol. 2017 Jul 26;8:486. doi: 10.3389/fphar.2017.00486. eCollection 2017. Front Pharmacol. 2017. PMID: 28798687 Free PMC article.
-
The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1.J Pers Med. 2021 Feb 5;11(2):103. doi: 10.3390/jpm11020103. J Pers Med. 2021. PMID: 33562658 Free PMC article. Review.
-
Rhizoma Coptidis: A Potential Cardiovascular Protective Agent.Front Pharmacol. 2016 Oct 7;7:362. doi: 10.3389/fphar.2016.00362. eCollection 2016. Front Pharmacol. 2016. PMID: 27774066 Free PMC article. Review.
-
Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among Eastern Finnish men.PLoS One. 2013 May 21;8(5):e64107. doi: 10.1371/journal.pone.0064107. Print 2013. PLoS One. 2013. PMID: 23700460 Free PMC article.
-
Tartaric acid-based amphiphilic macromolecules with ether linkages exhibit enhanced repression of oxidized low density lipoprotein uptake.Biomaterials. 2015 Jun;53:32-9. doi: 10.1016/j.biomaterials.2015.02.038. Epub 2015 Mar 7. Biomaterials. 2015. PMID: 25890704 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources